Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00232219|
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : May 5, 2015
The purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion.
Atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion.
Cardioversion involves resetting the heart back to normal with the use of electric current.
There is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion.
Fish oil supplements may be of benefit to patients with heart problems Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: Fish oil||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Use of Fish Oils to Reduce Recurrence of Atrial Fibrillation Following DC Cardioversion.|
|Study Start Date :||January 2003|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||November 2013|
No Intervention: Control
No fish oil exposure
Experimental: Fish oil
Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
|Drug: Fish oil|
- Recurrence of atrial fibrillation followed cardioversion [ Time Frame: 1 year ]
- Safety and tolerability [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00232219
|Royal Melbourne hospital|
|Melbourne, Victoria, Australia, 3050|
|Principal Investigator:||Paul Sparks, MBBS, PhD. FRACP||Melbourne Health|